Catalyst Funds Management’s Cabaletta Bio CABA Stock Holding History

Catalyst Funds Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,300	Closed	-$57.3K	–	690
2026 Q1	$57.3K	Buy	+21,300	New	+$59.1K	0.01%	532
2025 Q3	–	Sell	-21,000	Closed	-$31.9K	–	513
2025 Q2	$31.9K	Buy	+21,000	New	+$32.8K	0.01%	400
2024 Q3	–	Sell	-9,600	Closed	-$71.8K	–	1328
2024 Q2	$71.8K	Buy	9,600 +400	+4%	+$4.9K	0.02%	351
2024 Q1	$157K	Buy	+9,200	New	+$197K	0.04%	303

Other funds holding CABA

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Catalyst Funds Management's CABA Position: Q2 2026 in Review

Catalyst Funds Management sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 21,300 shares — an estimated $57.3K sold.

Catalyst Funds Management first reported a position in CABA in Q1 2024 and held it in 4 quarters. The position peaked at $157K in Q1 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

Catalyst Funds Management reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 21,300 Cabaletta Bio shares in Q2 2026, an estimated $57.3K.
Catalyst Funds Management first reported a position in Cabaletta Bio in Q1 2024 and held it in 4 quarters.
Catalyst Funds Management's Cabaletta Bio position peaked at $157K in Q1 2024.
140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.